Semin Neurol 2011; 31(2): 184-193
DOI: 10.1055/s-0031-1277989
© Thieme Medical Publishers

Toxic Encephalopathy

Michael R. Dobbs1 , 2
  • 1Department of Neurology, University of Kentucky, College of Medicine, College of Public Health, Lexington, Kentucky
  • 2Department of Preventive Medicine, University of Kentucky, College of Medicine, College of Public Health, Lexington, Kentucky
Further Information

Publication History

Publication Date:
17 May 2011 (online)

ABSTRACT

Neurotoxic exposures are common. Although there are myriad substances that can cause encephalopathy, this review focuses on common environmental neurotoxins, such as select heavy metals, organic industrial toxins, and pesticides. The central nervous system is susceptible to toxic injury, and many environmental neurotoxins are capable of causing encephalopathy. When a patient presents with toxic encephalopathy, the differential diagnosis is initially broad. The clinical presentation after exposure to a toxin varies in severity among patients. Arriving at the correct diagnosis is often a diagnostic challenge. The importance of taking a good history and performing a comprehensive examination cannot be overemphasized. Neuroimaging and neurophysiologic testing typically play ancillary roles. Confirmatory laboratory testing is available for some toxins. Treatment of most toxic encephalopathies is not supported by clinical trials; additional research is needed in the field.

REFERENCES

  • 1 Hunter D. The Diseases of Occupations. 6th ed. London: Hodderand Stoughton; 1978: 251
  • 2 Anger W K. Workplace exposures. In: Annau Z, ed. Neurobehavioral Toxicology. Baltimore, MD: Johns Hopkins; 1986
  • 3 National Institute for Occupational Safety and Health .National Occupational Hazard Survey, 1972–74. DHEW Publication No. (NIOSH) 78–114. Cincinnati, OH: National Institute for Occupational Health and Safety; 1977
  • 4 Spencer P S, Schaumburg H H. Experimental and Clinical Neurotoxicology. New York: Oxford University Press; 2000
  • 5 Dobbs M R. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia: Saunders; 2009
  • 6 Grandjean P, Landrigan P J. Developmental neurotoxicity of industrial chemicals.  Lancet. 2006;  368 (9553) 2167-2178
  • 7 Feldman R G. Approach to Diagnosis: Occupational and Environmental Neurotoxicology. Philadelphia: Lippincott-Raven; 1999
  • 8 Bull S. Review of Environmental Chemicals and Neurotoxicity: Focus on Neurological Diseases. Didcot: Centre for Radiation, Chemical and Environmental Hazards; 2007
  • 9 Zuccoli G, Siddiqui N, Cravo I, Bailey A, Gallucci M, Harper C G. Neuroimaging findings in alcohol-related encephalopathies.  AJR Am J Roentgenol. 2010;  195 (6) 1378-1384
  • 10 Brust J C. Ethanol and cognition: indirect effects, neurotoxicity and neuroprotection: a review.  Int J environ Res Public Health. 2010;  7 (4) 1540-1557
  • 11 Brust J C. Acute neurologic complications of drug and alcohol abuse.  J Acquir Immune Defic Syndr. 2002;  31 (Suppl 2) S29-S34
  • 12 Dobbs M R. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia: Saunders; 2009. chapters 30–34
  • 13 Chang K H, Han M H, Kim H S, Wie B A, Han M C. Delayed encephalopathy after acute carbon monoxide intoxication: MR imaging features and distribution of cerebral white matter lesions.  Radiology. 1992;  184 (1) 117-122
  • 14 Merimsky O, Loewenstein A, Chaitchik S. Cortical blindness—a catastrophic side effect of vincristine.  Anticancer Drugs. 1992;  3 (4) 371-373
  • 15 Merimsky O, Nisipeanu P, Loewenstein A, Reider-Groswasser I, Chaitchik S. Interferon-related cortical blindness.  Cancer Chemother Pharmacol. 1992;  29 (4) 329-330
  • 16 Young D C, Mitchell A, Kessler J, Christman J E. Cortical blindness and seizures possibly related to cisplatin, vinblastine, and bleomycin treatment of ovarian dysgerminoma.  J Am Osteopath Assoc. 1993;  93 (4) 502-504, 507
  • 17 Filley C M. Toxic leukoencephalopathy.  Clin Neuropharmacol. 1999;  22 (5) 249-260
  • 18 Moawad F J, Hartzell J D, Biega T J, Lettieri C J. Transient blindness due to posterior reversible encephalopathy syndrome following ephedra overdose.  South Med J. 2006;  99 (5) 511-514
  • 19 Fugate J E, Claassen D O, Cloft H J, Kallmes D F, Kozak O S, Rabinstein A A. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.  Mayo Clin Proc. 2010;  85 (5) 427-432
  • 20 Mueller-Mang C, Mang T, Pirker A, Klein K, Prchla C, Prayer D. Posterior reversible encephalopathy syndrome: do predisposing risk factors make a difference in MRI appearance?.  Neuroradiology. 2009;  51 (6) 373-383
  • 21 Cooney M J, Bradley W G, Symko S C, Patel S T, Groncy P K. Hypertensive encephalopathy: complication in children treated for myeloproliferative disorders—report of three cases.  Radiology. 2000;  214 (3) 711-716
  • 22 Morris E B, Laningham F H, Sandlund J T, Khan R B. Posterior reversible encephalopathy syndrome in children with cancer.  Pediatr Blood Cancer. 2007;  48 (2) 152-159
  • 23 Sánchez-Carpintero R, Narbona J, López de Mesa R, Arbizu J, Sierrasesúmaga L. Transient posterior encephalopathy induced by chemotherapy in children.  Pediatr Neurol. 2001;  24 (2) 145-148
  • 24 Pihko H, Tyni T, Virkola K et al.. Transient ischemic cerebral lesions during induction chemotherapy for acute lymphoblastic leukemia.  J Pediatr. 1993;  123 (5) 718-724
  • 25 Dzudie A, Boissonnat P, Roussoulieres A et al.. Cyclosporine-related posterior reversible encephalopathy syndrome after heart transplantation: should we withdraw or reduce cyclosporine?: case reports.  Transplant Proc. 2009;  41 (2) 716-720
  • 26 Saeed B, Abou-Zor N, Amer Z, Kanani I, Hilal M. Cyclosporin-A induced posterior reversible encephalopathy syndrome.  Saudi J Kidney Dis Transpl. 2008;  19 (3) 439-442
  • 27 Cosottini M, Lazzarotti G, Ceravolo R, Michelassi M C, Canapicchi R, Murri L. Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review.  Eur J Neurol. 2003;  10 (4) 461-462
  • 28 Vahidnia A, van der Voet G B, de Wolff F A. Arsenic neurotoxicity—a review.  Hum Exp Toxicol. 2007;  26 (10) 823-832
  • 29 Szlatenyi C S, Wang R Y. Encephalopathy and cranial nerve palsies caused by intentional trichloroethylene inhalation.  Am J Emerg Med. 1996;  14 (5) 464-466
  • 30 McCunney R J. Diverse manifestations of trichloroethylene.  Br J Ind Med. 1988;  45 (2) 122-126
  • 31 Greenberg S A. Acute demyelinating polyneuropathy with arsenic ingestion.  Muscle Nerve. 1996;  19 (12) 1611-1613
  • 32 London Z, Albers J W. Toxic neuropathies associated with pharmaceutic and industrial agents.  Neurol Clin. 2007;  25 (1) 257-276
  • 33 Bartynski W S. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.  AJNR Am J Neuroradiol. 2008;  29 (6) 1036-1042
  • 34 Bartynski W S, Boardman J F. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome.  AJNR Am J Neuroradiol. 2007;  28 (7) 1320-1327
  • 35 Oliver L. Laboratory assessment of exposure to neurotoxic agents. In: Dobbs M R, ed. Clinical Neurotoxicology: Syndromes, Substances, Environments. Philadelphia: Saunders; 2009: 213-221
  • 36 Schwartz B S, Lee B K, Lee G S et al.. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers.  Am J Epidemiol. 2001;  153 (5) 453-464
  • 37 Campara P, D'Andrea F, Micciolo R, Savonitto C, Tansella M, Zimmermann-Tansella C. Psychological performance of workers with blood-lead concentration below the current threshold limit value.  Int Arch Occup Environ Health. 1984;  53 (3) 233-246
  • 38 Stokes L, Letz R, Gerr F et al.. Neurotoxicity in young adults 20 years after childhood exposure to lead: the Bunker Hill experience.  Occup Environ Med. 1998;  55 (8) 507-516
  • 39 Landrigan P J, Todd A C. Lead poisoning.  West J Med. 1994;  161 (2) 153-159
  • 40 Saryan L A, Zenz C. Lead and its compounds. In: Saryan L A, Zenz C, eds. Occupational Medicine. 3rd ed. St. Louis, MO: Mosby; 1994: 506-541
  • 41 Karri S K, Saper R B, Kales S N. Lead encephalopathy due to traditional medicines.  Curr Drug Saf. 2008;  3 (1) 54-59
  • 42 Canfield R L, Henderson Jr C R, Cory-Slechta D A, Cox C, Jusko T A, Lanphear B P. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter.  N Engl J Med. 2003;  348 (16) 1517-1526
  • 43 Perelman S, Hertz-Pannier L, Hassan M, Bourrillon A. Lead encephalopathy mimicking a cerebellar tumor.  Acta Paediatr. 1993;  82 (4) 423-425
  • 44 Tüzün M, Tüzün D, Salan A, Hekimoğlu B. Lead encephalopathy: CT and MR findings.  J Comput Assist Tomogr. 2002;  26 (3) 479-481
  • 45 Reyes P F, Gonzalez C F, Zalewska M K, Besarab A. Intracranial calcification in adults with chronic lead exposure.  AJR Am J Roentgenol. 1986;  146 (2) 267-270
  • 46 American Academy of Pediatrics Committee on Environmental Health . Lead exposure in children: prevention, detection, and management.  Pediatrics. 2005;  116 (4) 1036-1046
  • 47 Freeman J W, Couch J R. Prolonged encephalopathy with arsenic poisoning.  Neurology. 1978;  28 (8) 853-855
  • 48 Bolla-Wilson K, Bleecker M L. Neuropsychological impairment following inorganic arsenic exposure.  J Occup Med. 1987;  29 (6) 500-503
  • 49 Ratnaike R N. Acute and chronic arsenic toxicity.  Postgrad Med J. 2003;  79 (933) 391-396
  • 50 Vahidnia A, van der Voet G B, de Wolff F A. Arsenic neurotoxicity—a review.  Hum Exp Toxicol. 2007;  26 (10) 823-832
  • 51 London Z, Albers J W. Toxic neuropathies associated with pharmaceutic and industrial agents.  Neurol Clin. 2007;  25 (1) 257-276
  • 52 Matschullat J. Arsenic in the geosphere—a review.  Sci Total Environ. 2000;  249 (1-3) 297-312
  • 53 Mukherjee S C, Rahman M M, Chowdhury U K et al.. Neuropathy in arsenic toxicity from groundwater arsenic contamination in West Bengal, India.  J Environ. Sci Health A Tox Hazard Subst Environ Eng. 2003;  38 165-183
  • 54 Lund A. Distribution of thallium in the organism and its elimination.  Acta Pharmacol Toxicol (Copenh). 1956;  12 (3) 251-259
  • 55 Tromme I, Van Neste D, Dobbelaere F et al.. Skin signs in the diagnosis of thallium poisoning.  Br J Dermatol. 1998;  138 (2) 321-325
  • 56 Moeschlin S. Thallium poisoning.  Clin Toxicol. 1980;  17 (1) 133-146
  • 57 Mulkey J P, Oehme F W. A review of thallium toxicity.  Vet Hum Toxicol. 1993;  35 (5) 445-453
  • 58 Rusyniak D E, Kao L W, Nanagas K A et al.. Dimercaptosuccinic acid and Prussian Blue in the treatment of acute thallium poisoning in rats.  J Toxicol Clin Toxicol. 2003;  41 (2) 137-142
  • 59 Chalela J A, Bonillha L, Neyens R, Hays A. Manganese encephalopathy: an under-recognized condition in the intensive care unit.  Neurocrit Care. 2010; December 21;  (Epub ahead of print)
  • 60 Hauser R A, Zesiewicz T A, Martinez C, Rosemurgy A S, Olanow C W. Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease.  Can J Neurol Sci. 1996;  23 (2) 95-98
  • 61 Butterworth R F, Spahr L, Fontaine S, Layrargues G P. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy.  Metab Brain Dis. 1995;  10 (4) 259-267
  • 62 Sata F, Araki S, Murata K, Aono H. Behavior of heavy metals in human urine and blood following calcium disodium ethylenediamine tetraacetate injection: observations in metal workers.  J Toxicol Environ Health A. 1998;  54 (3) 167-178
  • 63 Herrero Hernandez E, Discalzi G, Valentini C et al.. Follow-up of patients affected by manganese-induced Parkinsonism after treatment with CaNa2EDTA.  Neurotoxicology. 2006;  27 (3) 333-339
  • 64 Siegler R W, Nierenberg D W, Hickey W F. Fatal poisoning from liquid dimethylmercury: a neuropathologic study.  Hum Pathol. 1999;  30 (6) 720-723
  • 65 Lee B K, Lee S H, Lee K M et al.. Dose-dependent increase in subjective symptom prevalence among toluene-exposed workers.  Ind Health. 1988;  26 (1) 11-23
  • 66 Lazar R B, Ho S U, Melen O, Daghestani A N. Multifocal central nervous system damage caused by toluene abuse.  Neurology. 1983;  33 (10) 1337-1340
  • 67 Yücel M, Takagi M, Walterfang M, Lubman D I. Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature.  Neurosci Biobehav Rev. 2008;  32 (5) 910-926
  • 68 Bernad P G, Newell S, Spyker D A. Neurotoxicity and behavior abnormalities in a cohort chronically exposed to trichloroethylene.  Vet Hum Toxicol. 1987;  29 475
  • 69 Perbellini L, Olivato D, Zedde A, Miglioranzi R. Acute trichloroethylene poisoning by ingestion: clinical and pharmacokinetic aspects.  Intensive Care Med. 1991;  17 (4) 234-235
  • 70 Feldman R G, White R F, Currie J N, Travers P H, Lessell S. Long-term follow-up after single toxic exposure to trichloroethylene.  Am J Ind Med. 1985;  8 (2) 119-126
  • 71 Lawrence W H, Partyka E K. Chronic dysphagia and trigeminal anesthesia after trichloroethylene exposure.  Ann Intern Med. 1981;  95 (6) 710
  • 72 Leandri M, Schizzi R, Scielzo C, Favale E. Electrophysiological evidence of trigeminal root damage after trichloroethylene exposure.  Muscle Nerve. 1995;  18 (4) 467-468
  • 73 Szlatenyi C S, Wang R Y. Encephalopathy and cranial nerve palsies caused by intentional trichloroethylene inhalation.  Am J Emerg Med. 1996;  14 (5) 464-466
  • 74 Gash D M, Rutland K, Hudson N L et al.. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity.  Ann Neurol. 2008;  63 (2) 184-192
  • 75 Occupational Safety and Health Administration. Occupational Safety and Health Guideline for Carbon Monoxide. Washington, DC: Department of Labor. Available at: http://www.osha.gov/SLTC/healthguidelines/carbonmonoxide/recognition.html Accessed January 2011
  • 76 Choi I S. Delayed neurologic sequelae in carbon monoxide intoxication.  Arch Neurol. 1983;  40 (7) 433-435
  • 77 Min S K. A brain syndrome associated with delayed neuropsychiatric sequelae following acute carbon monoxide intoxication.  Acta Psychiatr Scand. 1986;  73 (1) 80-86
  • 78 Rusyniak D E. Pearls and pitfalls in the approach to patients with neurotoxic syndromes.  Semin Neurol. 2001;  21 (4) 407-416
  • 79 Hardy K R, Thom S R. Pathophysiology and treatment of carbon monoxide poisoning.  J Toxicol Clin Toxicol. 1994;  32 (6) 613-629
  • 80 Gorman D, Drewry A, Huang Y L, Sames C. The clinical toxicology of carbon monoxide.  Toxicology. 2003;  187 (1) 25-38
  • 81 Blumenthal I. Carbon monoxide poisoning.  J R Soc Med. 2001;  94 (6) 270-272
  • 82 Tapeantong T, Poungvarin N. Delayed encephalopathy and cognitive sequelae after acute carbon monoxide poisoning: report of a case and review of the literature.  J Med Assoc Thai. 2009;  92 (10) 1374-1379
  • 83 National Research Council of The National Academies .Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC: The National Academies Press; 2007

Michael R DobbsM.D. 

740 South Limestone Street

Wing D Kentucky Clinic L-412, Lexington, KY 40536

Email: mrdobb0@email.uky.edu